Simponi(Janssen Biotech) filed at FDA and EMA for Ulcerative Colitis treatment - 19-Jul-2012

Janssen Biotech and Janssen Biologics have requested the FDAand European Medicines Agency to approve Simponi(golimumab) a treatment for "adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy." Simponi ,a once-monthly subcutaneously administered drug , received approvals in the United States, Europe and Canada in 2009 for the treatment of moderately to severely-active rheumatoid arthritis and, in combination with methotrexate, for active psoriatic arthritis and for active ankylosing spondylitis.

Related News

Related Gastroenterology Information

Related Gastroenterology Drugs

Back to top

Latest News

10 May 2015
22 May 2013
22 May 2013